Related Experiment Video
Updated: Jun 23, 2026
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
Published on: March 3, 2023
The minimal clinically important difference for the Sniffin' Sticks Identification Test-16 in patients with chronic
Christian K Pedersen1,2, Simon Høj1,2, Marie Høxbro1,2
1Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Background:
The Minimal Clinically Important Difference (MCID) reflects the smallest change in a test score perceived as relevant by the patient. MCIDs vary according to disease and clinical context. The Sniffin' Sticks Identification Test 16 (SSIT-16) is a commonly used smell assessment tool, but its MCID in severe chronic rhinosinusitis with nasal polyps (CRSwNP) is unknown.
Objective:
To determine the MCID of SSIT-16 in severe CRSwNP treated with biologics.
Materials And Methods:
We analysed change scores from baseline to week 24 in 313 patients. The MCID was estimated using anchor-based and distribution-based methods. Anchors included a visual analogue scale (VAS) for smell, the rhinologic domain of SNOT-22, and the smell/taste item of SNOT-22. Distribution-based analyses included half a standard deviation of baseline SSIT-16 scores, the standard error of measurement (SEM), and the individual-level smallest detectable change.
Results:
The smell VAS performed best and was therefore chosen as the primary anchor. The optimal ΔSSIT-16 cut-off, balancing sensitivity (78%) and specificity (84%), was 3.5 points. This estimate was supported by distribution-based, sensitivity, and subgroup analyses.
Conclusion And Significance:
An improvement of approximately 3.5 SSIT-16 points appears to reflect clinically meaningful change in biologically treated patients with severe CRSwNP and may serve as a pragmatic threshold for interpreting olfactory outcomes.
Insights
The Minimal Clinically Important Difference (MCID) for the Sniffin' Sticks Identification Test 16 (SSIT-16) in severe chronic rhinosinusitis with nasal polyps (CRSwNP) treated with biologics is approximately 3.5 points. This threshold signifies a meaningful improvement in olfactory function for these patients.
Area of Science:
- Otolaryngology
- Clinical Outcomes Research
- Olfactory Function Assessment
Background:
- The Minimal Clinically Important Difference (MCID) is crucial for interpreting patient-relevant changes in clinical assessments.
- The Sniffin' Sticks Identification Test 16 (SSIT-16) is a standard tool for smell assessment, but its MCID in severe chronic rhinosinusitis with nasal polyps (CRSwNP) remains undefined.
- Understanding the MCID of SSIT-16 is vital for evaluating treatment efficacy in CRSwNP patients, particularly those receiving biologic therapies.
Purpose of the Study:
- To establish the MCID for the SSIT-16 in patients with severe CRSwNP undergoing biologic treatment.
- To provide a quantitative measure for clinically significant olfactory improvement in this specific patient population.
Main Methods:
- A cohort of 313 patients with severe CRSwNP treated with biologics had their SSIT-16 scores analyzed from baseline to 24 weeks.
- Anchor-based methods utilized a visual analogue scale (VAS) for smell, SNOT-22 rhinologic domain, and SNOT-22 smell/taste item.
- Distribution-based methods included half standard deviation, standard error of measurement (SEM), and smallest detectable change.
Main Results:
- The smell VAS proved to be the most effective anchor.
- An SSIT-16 change score of 3.5 points demonstrated optimal balance between sensitivity (78%) and specificity (84%).
- This finding was corroborated by distribution-based analyses, sensitivity analyses, and subgroup analyses.
Conclusions:
- An improvement of approximately 3.5 points on the SSIT-16 represents a clinically meaningful change in olfactory function for patients with severe CRSwNP treated with biologics.
- This 3.5-point threshold can serve as a practical benchmark for assessing olfactory outcomes in this patient group.
Related Concept Videos
01:16Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
01:30Epistaxis
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...